Company webinar

Argenica Therapeutics (ASX:AGN)

Watch our webinar with Argenica Therapeutics, featuring Managing Director Dr. Liz Dallimore. An interview followed by live Q&A with the audience.

Date
August 16, 2024
Time
Where
Online
Entry
Free
Dr. Liz Dallimore
Dr. Liz Dallimore
Managing Director, Argenica Therapeutics (ASX:AGN)

About the company

Argenica Therapeutics Limited (ASX:AGN) is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries. In June 2021, the Company listed on the ASX, and has since completed a successful Phase 1 clinical trial proving the safety and tolerability of its drug in healthy human volunteers, and is currently dosing acute ischaemic stroke patients in a Phase 2 clinical trial in Australia. The Company has a favourable competitive landscape and commercial opportunity, with no other universal marketed drugs available to protect brain cells from death following stroke.

Key topics

  • Overview of Argenica Therapeutics
  • Opportunity in stroke
  • Phase 2 clinical trial
  • Competitive advantages in the Biotech industry
  • Key challenges
  • Team at Argenica
  • Catalysts and milestones for the next 12-18 months
  • Long-term outlook for the company

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →